Figure 1H shows that anaplastic lymphoma kinase (ALK) and AXL receptor tyrosine kinase ranked in the top 1000 suggested targets for NSCLC for several years before their first evidence by Soda et al.43 in 2007 and Wimmel et al.44 in 2001, and the first trials for the ALK inhibitor crizotinib (originally thought as a tyrosine-protein kinase MET specific inhibitor) in 200745 and the AXL inhibitor bemcetinib in 201046. This evidence concerns the gene AXL and non-small cell lung carcinoma.